Idorsia Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd

Laetitia Pouzol

Hamed Aissaoui

Sylvia Richard-Bildstein

Julien Pothier

Philippe Guerry

Francois Lehembre

Shuguang Yuan

Martine Clozel

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Pharmaceutical combination comprising ponesimod

The present invention relates to piperidine derivatives of formula (I) wherein Ar, Ar, R, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

Piperidine CXCR7 receptor modulators

The present invention relates to piperidine derivatives of formula (I) wherein Ar, Ar, R, R, Rand Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

Piperdine CXCR7 receptor modulators

Growing community of inventors

Allschwil, Switzerland

Laetitia Pouzol